A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 166, Issue 3, Pages 858-876
Publisher
Wiley
Online
2012-01-18
DOI
10.1111/j.1476-5381.2012.01859.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes
- (2011) Shixiong Tan et al. BIOCHEMICAL JOURNAL
- A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
- (2011) Stephen Jamieson et al. BIOCHEMICAL JOURNAL
- R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm
- (2011) K. Shide et al. BLOOD
- A theoretical entropy score as a single value to express inhibitor selectivity
- (2011) Joost CM Uitdehaag et al. BMC BIOINFORMATICS
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- Inhibition of Wnt/β-Catenin Signaling by p38 MAP Kinase Inhibitors Is Explained by Cross-Reactivity with Casein Kinase Iδ/ɛ
- (2011) Folkert Verkaar et al. CHEMISTRY & BIOLOGY
- In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
- (2011) Matthew P. Patricelli et al. CHEMISTRY & BIOLOGY
- High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors
- (2011) Chandrasekhar V. Miduturu et al. CHEMISTRY & BIOLOGY
- Dasatinib: An Anti-Tumour Agent via Src Inhibition
- (2011) Antonio Gnoni et al. CURRENT DRUG TARGETS
- MEK inhibitors: a patent review 2008 – 2010
- (2011) John I Trujillo EXPERT OPINION ON THERAPEUTIC PATENTS
- Selectivity of Kinase Inhibitor Fragments
- (2011) Paul Bamborough et al. JOURNAL OF MEDICINAL CHEMISTRY
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Navigating the kinome
- (2011) James T Metz et al. Nature Chemical Biology
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
- (2011) Pankaj Bhargava et al. Current Oncology Reports
- Using Small Molecules and Chemical Genetics To Interrogate Signaling Networks
- (2010) Scott M. Carlson et al. ACS Chemical Biology
- Aurora kinase inhibitors as anticancer molecules
- (2010) Hiroshi Katayama et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing
- (2010) Maria Gabriella Brasca et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo
- (2010) Jin-gui Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines
- (2010) M. Payton et al. CANCER RESEARCH
- Chemical approaches towards unravelling kinase-mediated signalling pathways
- (2010) David R. W. Hodgson et al. CHEMICAL SOCIETY REVIEWS
- Aurora-A kinase inhibitor scaffolds and binding modes
- (2010) Aixia Yan et al. DRUG DISCOVERY TODAY
- Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index
- (2010) Alan C. Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
- (2010) Nicholas D. Adams et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trends in Kinase Selectivity: Insights for Target Class-Focused Library Screening
- (2010) Shana L. Posy et al. JOURNAL OF MEDICINAL CHEMISTRY
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- Mitogen-Activated Protein Kinases Promote WNT/ -Catenin Signaling via Phosphorylation of LRP6
- (2010) I. Cervenka et al. MOLECULAR AND CELLULAR BIOLOGY
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- (2010) T. A. Yap et al. MOLECULAR CANCER THERAPEUTICS
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
- (2010) T. Shimomura et al. MOLECULAR CANCER THERAPEUTICS
- AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
- (2010) K. M. Grimshaw et al. MOLECULAR CANCER THERAPEUTICS
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- How melanomas bypass new therapy
- (2010) David Solit et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?
- (2010) Tamsin M. Lindstrom et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Inhibition of p38: Has the fat lady sung?
- (2009) Mark C. Genovese ARTHRITIS AND RHEUMATISM
- Extended kinase profile and properties of the protein kinase inhibitor nilotinib
- (2009) Paul W. Manley et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding
- (2009) Kyle A. Emmitte et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Small kinase assay panels can provide a measure of selectivity
- (2009) Peter Brandt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
- (2009) Jennifer P. Arbitrario et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
- (2009) S. Ali et al. CANCER RESEARCH
- Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds
- (2009) Jens-Uwe Peters et al. ChemMedChem
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
- (2009) Bryan T. MacDonald et al. DEVELOPMENTAL CELL
- G-protein-coupled receptor-focused drug discovery using a target class platform approach
- (2009) Ralf Heilker et al. DRUG DISCOVERY TODAY
- Revealing promiscuous drug–target interactions by chemical proteomics
- (2009) Marcus Bantscheff et al. DRUG DISCOVERY TODAY
- In vitrosafety pharmacology profiling: what else beyond hERG?
- (2009) Jacques Hamon et al. Future Medicinal Chemistry
- Discovery of 6-Aryl-7-alkoxyisoquinoline Inhibitors of IκB Kinase-β (IKK-β)
- (2009) John A. Christopher et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors
- (2009) Ted Kamenecka et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Novel, Highly Selective, Tight Binding I B Kinase-2 (IKK-2) Inhibitor: A Tool to Correlate IKK-2 Activity to the Fate and Functions of the Components of the Nuclear Factor- B Pathway in Arthritis-Relevant Cells and Animal Models
- (2009) G. Mbalaviele et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells
- (2009) U Rix et al. LEUKEMIA
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
- (2009) S. G. Buchanan et al. MOLECULAR CANCER THERAPEUTICS
- AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
- (2009) K. F. Byth et al. MOLECULAR CANCER THERAPEUTICS
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
- (2009) Tim P. Green et al. Molecular Oncology
- Target profiling of small molecules by chemical proteomics
- (2009) Uwe Rix et al. Nature Chemical Biology
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
- (2009) P. Schoffski ONCOLOGIST
- Protein kinase inhibitors: contributions from structure to clinical compounds
- (2009) Louise N. Johnson QUARTERLY REVIEWS OF BIOPHYSICS
- The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase
- (2008) Andrew K. Takle et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors
- (2008) Zhicai Wu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Potent and selective pyrazole-based inhibitors of B-Raf kinase
- (2008) Joshua D. Hansen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα
- (2008) K Mihara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-ones
- (2008) John Spencer et al. DALTON TRANSACTIONS
- Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2
- (2008) Joseph M. Gozgit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- p38 mitogen-activated protein kinase regulates canonical Wnt- -catenin signaling by inactivation of GSK3
- (2008) R. K. Bikkavilli et al. JOURNAL OF CELL SCIENCE
- Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
- (2008) Paul Bamborough et al. JOURNAL OF MEDICINAL CHEMISTRY
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- (2008) L L Remsing Rix et al. LEUKEMIA
- Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines
- (2008) Yasuyuki Deguchi et al. LEUKEMIA RESEARCH
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Network pharmacology: the next paradigm in drug discovery
- (2008) Andrew L Hopkins Nature Chemical Biology
- High-throughput kinase profiling as a platform for drug discovery
- (2008) David M. Goldstein et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitors of c-Jun N-terminal kinases—JuNK no more?
- (2007) Marie A. Bogoyevitch et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors
- (2007) John C. Hartnett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity
- (2007) Zhijian Zhao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started